Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
Matteo Lambertini(Ospedale Policlinico San Martino), Francesca Poggio(Ospedale Policlinico San Martino), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Fabio Puglisi(University of Udine), Claudia Bighin(Azienda Ospedaliera S.Maria), Filippo Montemurro(Roche (Switzerland)), Alessandra Fabi(Agostino Gemelli University Polyclinic), Giancarlo Bisagni, Benedetta Conte(Ospedale Policlinico San Martino), Francesco Cognetti(Apple (Israel)), Marco Bruzzone(Ospedale Policlinico San Martino), Mario Giuliano(Regione Campania), Anna Turletti(Ospedale Martini), Lucia Del Mastro(Ospedale Policlinico San Martino), Evandro de Azambuja(Université Libre de Bruxelles), Marcello Ceppi(Ospedale Policlinico San Martino), Antonio Durando(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Ylenia Urracci
Cited by 20
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
|British Journal of Cancer|2007|957